GeneHub’s Crowdfunding Flub

A campaign to build a direct-to-consumer genome sequencing service pulls the plug after two days of fundraising.

Written byKerry Grens
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

WIKIMEDIA, NATIONAL HUMAN GENOME RESEARCH INSTITUTELast week, Bio-IT World reported on the Kickstarter campaign of GeneHub, a would-be direct-to-consumer genome sequencing company. But just two days later, GeneHub pulled the project because its name violated the trademark of a different company, Genohub, Bio-IT reported September 25.

“Firstly, we’re far behind on the level of funding that we’d need to hit our $125k. But that in itself isn’t a reason to take it down early,” GeneHub announced on its Kickstarter page. “Yesterday we learned that there is a genomics company called Genohub that we were unaware of, putting the brand and video and everything we’ve worked so hard on squarely in ‘trademark violation’ zone.”

Genohub connects researchers who have sequencing needs with sequencing providers (Bio-IT World also wrote about that firm last year).

According to Re/code, GeneHub’s plan was to raise $125,000 through Kickstarter and offer whole-genome sequencing for customers at a pricetag of $3,490. The firm would not interpret the data for medical insight nor provide ancestry services, but allow customers ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • kerry grens

    Kerry served as The Scientist’s news director until 2021. Before joining The Scientist in 2013, she was a stringer for Reuters Health, the senior health and science reporter at WHYY in Philadelphia, and the health and science reporter at New Hampshire Public Radio. Kerry got her start in journalism as a AAAS Mass Media fellow at KUNC in Colorado. She has a master’s in biological sciences from Stanford University and a biology degree from Loyola University Chicago.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies